Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Diagnostic approach to and treatment of thyroid nodules

Douglas S Ross, MD
Section Editor
David S Cooper, MD
Deputy Editor
Jean E Mulder, MD


Thyroid nodules come to clinical attention when noted by the patient, by a physician during routine physical examination, or during a radiologic procedure, such as carotid ultrasonography, neck computed tomography (CT), or positron emission tomography (PET) scanning. Their clinical importance is primarily related to the need to exclude thyroid cancer, which accounts for 4.0 to 6.5 percent of all thyroid nodules in non-surgical series.

The diagnostic evaluation and treatment of thyroid nodules will be reviewed here. Fine needle aspiration (FNA) techniques and common cytopathologic findings are reviewed elsewhere. (See "Thyroid biopsy" and "Atlas of thyroid cytopathology".)


Several different disorders can cause thyroid nodules (table 1). The clinical importance of the thyroid nodule evaluation is primarily related to the need to exclude thyroid cancer, which is present in 4.0 to 6.5 percent of thyroid nodules [1-4]. The prevalence of cancer is higher in several groups:


Adults less than 30 or over 60 years old

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Aug 30, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Werk EE Jr, Vernon BM, Gonzalez JJ, et al. Cancer in thyroid nodules. A community hospital survey. Arch Intern Med 1984; 144:474.
  2. Belfiore A, Giuffrida D, La Rosa GL, et al. High frequency of cancer in cold thyroid nodules occurring at young age. Acta Endocrinol (Copenh) 1989; 121:197.
  3. Hegedüs L. Clinical practice. The thyroid nodule. N Engl J Med 2004; 351:1764.
  4. Lin JD, Chao TC, Huang BY, et al. Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. Thyroid 2005; 15:708.
  5. National Comprehensive Cancer Network http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on July 11, 2013).
  6. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1.
  7. Steele SR, Martin MJ, Mullenix PS, et al. The significance of incidental thyroid abnormalities identified during carotid duplex ultrasonography. Arch Surg 2005; 140:981.
  8. Hagag P, Strauss S, Weiss M. Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. Thyroid 1998; 8:989.
  9. Leenhardt L, Hejblum G, Franc B, et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab 1999; 84:24.
  10. Nam-Goong IS, Kim HY, Gong G, et al. Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) 2004; 60:21.
  11. Boelaert K, Horacek J, Holder RL, et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 2006; 91:4295.
  12. Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008; 93:809.
  13. McLeod DS, Cooper DS, Ladenson PW, et al. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid 2014; 24:35.
  14. Solbiati L, Volterrani L, Rizzatto G, et al. The thyroid gland with low uptake lesions: evaluation by ultrasound. Radiology 1985; 155:187.
  15. Radecki PD, Arger PH, Arenson RL, et al. Thyroid imaging: comparison of high-resolution real-time ultrasound and computed tomography. Radiology 1984; 153:145.
  16. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997; 126:226.
  17. Marqusee E, Benson CB, Frates MC, et al. Usefulness of ultrasonography in the management of nodular thyroid disease. Ann Intern Med 2000; 133:696.
  18. Reschini E, Ferrari C, Castellani M, et al. The trapping-only nodules of the thyroid gland: prevalence study. Thyroid 2006; 16:757.
  19. Dige-Petersen H, Kroon S, Vadstrup S, et al. A comparison of 99Tc and 123I scintigraphy in nodular thyroid disorders. Eur J Nucl Med 1978; 3:1.
  20. Shambaugh GE 3rd, Quinn JL, Oyasu R, Freinkel N. Disparate thyroid imaging. Combined studies with sodium pertechnetate Tc 99m and radioactive iodine. JAMA 1974; 228:866.
  21. Tennvall J, Cederquist E, Möller T, et al. Preoperative scintigraphy with correlation to cytology and histopathology in carcinoma of the thyroid. Acta Radiol Oncol 1983; 22:183.
  22. Turner JW, Spencer RP. Thyroid carcinoma presenting as a pertechnetate "hot" nodule, but without 131I uptake: case report. J Nucl Med 1976; 17:22.
  23. Arnold JE, Pinsky S. Comparison of 99mTc and 123I for thyroid imaging. J Nucl Med 1976; 17:261.
  24. Blum M, Goldman AB. Improved diagnosis of "nondelineated" thyroid nodules by oblique scintillation scanning and echography. J Nucl Med 1975; 16:713.
  25. Nelson RL, Wahner HW, Gorman CA. Rectilinear thyroid scanning as a predictor of malignancy. Ann Intern Med 1978; 88:41.
  26. Miller JM. Re: thyroid carcinoma in an autonomously functioning nodule. J Nucl Med 1980; 21:296.
  27. Hoving J, Piers DA, Vermey A, Oosterhuis JW. Carcinoma in hyperfunctioning thyroid nodule in recurrent hyperthyroidism. Eur J Nucl Med 1981; 6:131.
  28. Hayes FJ, Sheahan K, Heffernan A, McKenna TJ. Aggressive thyroid cancer associated with toxic nodular goitre. Eur J Endocrinol 1996; 134:366.
  29. Ashcraft MW, Van Herle AJ. Management of thyroid nodules. II: Scanning techniques, thyroid suppressive therapy, and fine needle aspiration. Head Neck Surg 1981; 3:297.
  30. Ramos CD, Zantut-Wittmann DE, Tambascia MA, et al. Thyroid suppression test with L-thyroxine and [99mTc] pertechnetate. Clin Endocrinol (Oxf) 2000; 52:471.
  31. Molitch ME, Beck JR, Dreisman M, et al. The cold thyroid nodule: an analysis of diagnostic and therapeutic options. Endocr Rev 1984; 5:185.
  32. Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med 2005; 142:926.
  33. Miller JM, Hamburger JI, Kini S. Diagnosis of thyroid nodules. Use of fine-needle aspiration and needle biopsy. JAMA 1979; 241:481.
  34. Hamberger B, Gharib H, Melton LJ 3rd, et al. Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care. Am J Med 1982; 73:381.
  35. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002; 87:1941.
  36. McCartney CR, Stukenborg GJ. Decision analysis of discordant thyroid nodule biopsy guideline criteria. J Clin Endocrinol Metab 2008; 93:3037.
  37. Tang AL, Falciglia M, Yang H, et al. Validation of American Thyroid Association Ultrasound Risk Assessment of Thyroid Nodules Selected for Ultrasound Fine-Needle Aspiration. Thyroid 2017; 27:1077.
  38. Brito JP, Ito Y, Miyauchi A, Tuttle RM. A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. Thyroid 2016; 26:144.
  39. Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 2009; 94:1748.
  40. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008; 36:425.
  41. Hodak SP, Rosenthal DS, American Thyroid Association Clinical Affairs Committee. Information for clinicians: commercially available molecular diagnosis testing in the evaluation of thyroid nodule fine-needle aspiration specimens. Thyroid 2013; 23:131.
  42. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013; 381:1058.
  43. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011; 96:3390.
  44. Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 2014; 120:3627.
  45. Nikiforov YE, Carty SE, Chiosea SI, et al. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. Thyroid 2015; 25:1217.
  46. Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab 2010; 95:5296.
  47. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012; 367:705.
  48. McIver B, Castro MR, Morris JC, et al. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2014; 99:4069.
  49. Li H, Robinson KA, Anton B, et al. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2011; 96:E1719.
  50. Labourier E, Shifrin A, Busseniers AE, et al. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology. J Clin Endocrinol Metab 2015; 100:2743.
  51. Durante C, Costante G, Lucisano G, et al. The natural history of benign thyroid nodules. JAMA 2015; 313:926.
  52. Costante G, Filetti S. Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease? Oncologist 2011; 16:49.
  53. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89:163.
  54. Niccoli P, Wion-Barbot N, Caron P, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 1997; 82:338.
  55. Karges W, Dralle H, Raue F, et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004; 112:52.
  56. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154:787.
  57. Hodak SP, Burman KD. The calcitonin conundrum--is it time for routine measurement of serum calcitonin in patients with thyroid nodules? J Clin Endocrinol Metab 2004; 89:511.
  58. Daniels GH. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. Thyroid 2011; 21:1199.
  59. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25:567.
  60. Colombo C, Verga U, Mian C, et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. J Clin Endocrinol Metab 2012; 97:905.
  61. Mian C, Perrino M, Colombo C, et al. Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. J Clin Endocrinol Metab 2014; 99:1656.
  62. Horvit PK, Gagel RF. The goitrous patient with an elevated serum calcitonin--what to do? J Clin Endocrinol Metab 1997; 82:335.
  63. Ozgen AG, Hamulu F, Bayraktar F, et al. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid 1999; 9:579.
  64. Hahm JR, Lee MS, Min YK, et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 2001; 11:73.
  65. Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007; 92:450.
  66. Machens A, Hoffmann F, Sekulla C, Dralle H. Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer. Endocr Relat Cancer 2009; 16:1291.
  67. Chambon G, Alovisetti C, Idoux-Louche C, et al. The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients. J Clin Endocrinol Metab 2011; 96:75.
  68. Machens A, Dralle H. Biological relevance of medullary thyroid microcarcinoma. J Clin Endocrinol Metab 2012; 97:1547.
  69. Karanikas G, Moameni A, Poetzi C, et al. Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. J Clin Endocrinol Metab 2004; 89:515.
  70. Vierhapper H, Niederle B, Bieglmayer C, et al. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 2005; 15:1267.
  71. Borget I, De Pouvourville G, Schlumberger M. Editorial: Calcitonin determination in patients with nodular thyroid disease. J Clin Endocrinol Metab 2007; 92:425.
  72. Rink T, Truong PN, Schroth HJ, et al. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease. Thyroid 2009; 19:327.
  73. Herrmann BL, Schmid KW, Goerges R, et al. Calcitonin screening and pentagastrin testing: predictive value for the diagnosis of medullary carcinoma in nodular thyroid disease. Eur J Endocrinol 2010; 162:1141.
  74. Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994; 78:826.
  75. Toledo SP, Lourenço DM Jr, Santos MA, et al. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo) 2009; 64:699.
  76. Erdogan MF, Gursoy A, Kulaksizoglu M. Long-term effects of elevated gastrin levels on calcitonin secretion. J Endocrinol Invest 2006; 29:771.
  77. Wang TS, Ocal IT, Sosa JA, et al. Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma. Thyroid 2008; 18:889.
  78. Dora JM, Canalli MH, Capp C, et al. Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature. Thyroid 2008; 18:895.
  79. Clark OH. TSH suppression in the management of thyroid nodules and thyroid cancer. World J Surg 1981; 5:39.
  80. Schneider AB, Bekerman C, Leland J, et al. Thyroid nodules in the follow-up of irradiated individuals: comparison of thyroid ultrasound with scanning and palpation. J Clin Endocrinol Metab 1997; 82:4020.
  81. Wilhelm SM, Robinson AV, Krishnamurthi SS, Reynolds HL. Evaluation and management of incidental thyroid nodules in patients with another primary malignancy. Surgery 2007; 142:581.
  82. Soelberg KK, Bonnema SJ, Brix TH, Hegedüs L. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid 2012; 22:918.
  83. Van den Bruel A, Maes A, De Potter T, et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 2002; 87:1517.
  84. Nam SY, Roh JL, Kim JS, et al. Focal uptake of (18)F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol (Oxf) 2007; 67:135.
  85. Kim WB, Han SM, Kim TY, et al. Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease. Clin Endocrinol (Oxf) 2004; 60:719.
  86. Kwak JY, Koo H, Youk JH, et al. Value of US correlation of a thyroid nodule with initially benign cytologic results. Radiology 2010; 254:292.
  87. Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 2007; 111:508.
  88. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2009; 19:1159.
  89. Wang CC, Friedman L, Kennedy GC, et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid 2011; 21:243.
  90. Kuma K, Matsuzuka F, Yokozawa T, et al. Fate of untreated benign thyroid nodules: results of long-term follow-up. World J Surg 1994; 18:495.
  91. Lucas A, Llatjós M, Salinas I, et al. Fine-needle aspiration cytology of benign nodular thyroid disease. Value of re-aspiration. Eur J Endocrinol 1995; 132:677.
  92. Merchant SH, Izquierdo R, Khurana KK. Is repeated fine-needle aspiration cytology useful in the management of patients with benign nodular thyroid disease? Thyroid 2000; 10:489.
  93. Erdoğan MF, Kamel N, Aras D, et al. Value of re-aspirations in benign nodular thyroid disease. Thyroid 1998; 8:1087.
  94. Orlandi A, Puscar A, Capriata E, Fideleff H. Repeated fine-needle aspiration of the thyroid in benign nodular thyroid disease: critical evaluation of long-term follow-up. Thyroid 2005; 15:274.
  95. Kim SY, Han KH, Moon HJ, et al. Thyroid nodules with benign findings at cytologic examination: results of long-term follow-up with US. Radiology 2014; 271:272.
  96. Alexander EK, Hurwitz S, Heering JP, et al. Natural history of benign solid and cystic thyroid nodules. Ann Intern Med 2003; 138:315.
  97. Nou E, Kwong N, Alexander LK, et al. Determination of the optimal time interval for repeat evaluation after a benign thyroid nodule aspiration. J Clin Endocrinol Metab 2014; 99:510.
  98. Olson MT, Clark DP, Erozan YS, Ali SZ. Spectrum of risk of malignancy in subcategories of 'atypia of undetermined significance'. Acta Cytol 2011; 55:518.
  99. Nayar R, Ivanovic M. The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer 2009; 117:195.
  100. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol 2010; 118:17.
  101. Bongiovanni M, Crippa S, Baloch Z, et al. Comparison of 5-tiered and 6-tiered diagnostic systems for the reporting of thyroid cytopathology: a multi-institutional study. Cancer Cytopathol 2012; 120:117.
  102. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70:511.
  103. Alexander EK, Schorr M, Klopper J, et al. Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab 2014; 99:119.
  104. Brauner E, Holmes BJ, Krane JF, et al. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules. Thyroid 2015; 25:789.
  105. Yip L, Wharry LI, Armstrong MJ, et al. A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Ann Surg 2014; 260:163.
  106. Alexander EK, Heering JP, Benson CB, et al. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab 2002; 87:4924.
  107. Samir AE, Vij A, Seale MK, et al. Ultrasound-guided percutaneous thyroid nodule core biopsy: clinical utility in patients with prior nondiagnostic fine-needle aspirate. Thyroid 2012; 22:461.
  108. Moon HJ, Kwak JY, Choi YS, Kim EK. How to manage thyroid nodules with two consecutive non-diagnostic results on ultrasonography-guided fine-needle aspiration. World J Surg 2012; 36:586.